{"id":468,"date":"2026-03-09T08:59:49","date_gmt":"2026-03-09T07:59:49","guid":{"rendered":"https:\/\/semmelweis.hu\/onkologiai-tanszek\/?p=468"},"modified":"2026-03-09T09:01:05","modified_gmt":"2026-03-09T08:01:05","slug":"new-publication","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/onkologiai-tanszek\/en\/2026\/03\/09\/new-publication\/","title":{"rendered":"New publication: pilot study and meta-analysis on mEHT in gynecological cancers"},"content":{"rendered":"<p>At the enf of February 2026, our department\u2019s new scientific paper was published in the journal of Medical Sciences (<a href=\"https:\/\/doi.org\/10.3390\/medsci14010105\">click here to read the complete pubilcation on the journal\u2019s website<\/a>).<\/p>\n<h5>Details of the publication:<\/h5>\n<ul>\n<li><strong>Authors:<\/strong> Panczel I, Herold M, Borbenyi E, Horanyi D, Novak, Z, Dank M, Szasz AM, Herdol Z<\/li>\n<li><strong>Title:<\/strong> Survival Difference in Advanced-Stage Cervical and Ovarian Cancer Patients Treated with Concomitant Modulated Electro-Hyperthermia in Comparison to Classic Treatment Modalities: Results of a Pilot Study and Meta-Analysis<\/li>\n<li><strong>Publication data:<\/strong> Med. Sci. 2026, 14(1):105<\/li>\n<li><strong>Abstract:<br \/>\n<em>Background:<\/em><\/strong> Modulated electro-hyperthermia (mEHT) is one of the latest advancements in the field of oncological hyperthermia. Previous studies investigating mEHT revealed that it is safe and effective; however, no meta-analysis was conducted either in cervical or ovarian cancer. <em><strong>Methods:<\/strong><\/em> A single-institute pilot case series and a meta-analysis were conducted. Advanced stage cervical and ovarian cancer cases were included. In the pilot study, mEHT treatments were conducted using the Oncotherm EHY-2000+ and the EHY-2030 devices with 2\u20133 treatment sessions per week. <em><strong>Results:<\/strong><\/em> For the meta-analysis, a total of five studies were identified, with 160 and 31 cervical and ovarian cancer patients, respectively. In addition, 175 standard-of-care-treated cervical cancer patients were also identified as controls. The 1- and 2-year survival rate of the cervical cancer patients treated with mEHT was 87.61% [95% confidence interval (CI): 71.31\u2013100%] and 78.13% (95% CI: 53.02\u2013100%). Compared to the controls, the 2-year survival rates (78.13% vs. 58.86%) were significantly better in the mEHT-treated cohorts (odds ratio: 0.4143, p = 0.0441; hazard rate: 0.6607, p = 0.0103). The 1- and 2-year survival rates of ovarian cancer patients were 45.46% (95% CI: 5.97\u201384.95%) and 32.83% (95% CI: 0\u201379.57%), respectively. The result of our institutional data strengthened the results of the meta-analysis. <em><strong>Conclusions:<\/strong><\/em> Using mEHT, a significantly higher 2-year survival rate can be achieved in cervical cancer. In this setting, a wider testing\/application of the modality is warranted. In the case of ovarian tumors, the available knowledge is minimal, and applicability and efficacy studies are urgently needed.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>At the enf of February 2026, our department\u2019s new scientific paper was published in the journal of Medical Sciences ( <a href=\"https:\/\/doi.org\/10.3390\/medsci14010105\">click here to read the complete pubilcation on the journal\u2019s website<\/a> ). Details of the publication: Authors: Panczel I, Herold M, Borbenyi E, Horanyi D, Novak, Z, Dank M, Szasz AM, Herdol Z Title: Survival Difference in Advanced-Stage Cervical and Ovarian Cancer Patients Treated with Concomitant &hellip;<\/p>\n","protected":false},"author":102054,"featured_media":446,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[14],"tags":[],"class_list":["post-468","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/onkologiai-tanszek\/wp-json\/wp\/v2\/posts\/468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/onkologiai-tanszek\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/semmelweis.hu\/onkologiai-tanszek\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/onkologiai-tanszek\/wp-json\/wp\/v2\/users\/102054"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/onkologiai-tanszek\/wp-json\/wp\/v2\/comments?post=468"}],"version-history":[{"count":2,"href":"https:\/\/semmelweis.hu\/onkologiai-tanszek\/wp-json\/wp\/v2\/posts\/468\/revisions"}],"predecessor-version":[{"id":470,"href":"https:\/\/semmelweis.hu\/onkologiai-tanszek\/wp-json\/wp\/v2\/posts\/468\/revisions\/470"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/onkologiai-tanszek\/wp-json\/wp\/v2\/media\/446"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/onkologiai-tanszek\/wp-json\/wp\/v2\/media?parent=468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/onkologiai-tanszek\/wp-json\/wp\/v2\/categories?post=468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/onkologiai-tanszek\/wp-json\/wp\/v2\/tags?post=468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}